Secondary malignancies are well established complication in long-term survivors after allogeneic stem-cell transplantation (SCT) with myeloablative conditioning (MAC). Fludarabine-based reduced-intensity (RIC) and reduced-toxicity conditioning (RTC) regimens are increasingly used in the last decade; however, due to limited long-term follow-up, there is no data on secondary malignancies in this setting. The records of 931 consecutive patients given allogeneic SCT with MAC (n ¼ 257), RIC (n ¼ 449) or RTC (n ¼ 225), in a single institution over a 13-year period, were reviewed. Twenty-seven patients had secondary malignancy, diagnosed a median of 43 months (7 months-11.5 years) after SCT. The 10-year cumulative incidence was 5.6% (95% confidence interval (CI), 3.6-8.7), twice the expected rate in matched normal population. The incidence was 1.7, 7.4 and 5.7% after MAC, RIC and RTC, respectively (P ¼ 0.02). Multivariate analysis identified fludarabine-based conditioning (hazard ratio (HR) 3.5, P ¼ 0.05), moderatesevere chronic graft-versus-host disease (HR 2.8, P ¼ 0.01) and diagnosis of chronic myeloproliferative or non-malignant disease (HR 0.2, P ¼ 0.04) as risk-factors for secondary malignancy. The related 10-year mortality rate was 2.4% (95% CI, 1.0-5.4). In conclusion, the risk of secondary malignancies is not reduced and is even possibly increased in the era of fludarabine-based RIC/RTC. Patients and physicians should be aware of this association and life-long cancer screening is required for all transplant survivors.
INTRODUCTION
Allogeneic hematopoietic stem-cell transplantation (SCT) is a potentially curative therapy for patients with a variety of malignant and non-malignant hematological disorders. Over the last decades, substantial improvement has been achieved in SCT outcomes mostly owing to improved supportive care and SCT techniques. 1 A larger proportion of SCT recipients are now longterm survivors. However, they remain at risk for late complications and late morbidity and mortality that is higher than their age-and gender-matched normal population. 2 Secondary malignancies are rare but well-established complication after allogeneic SCT. [2] [3] [4] [5] [6] [7] [8] [9] The cumulative incidence is increasing after SCT with no apparent plateau and is estimated to be 1-6% and 2-15%, 10 and 15 years after SCT, respectively. The Center for International Blood and Marrow Transplant Research (CIBMTR) and the Fred Hutchinson Cancer Research Center conducted the largest analysis to date of secondary malignancies among 28 874 SCT recipients. 8 Secondary malignancies were observed in 189 patients (invasive solid cancer in 153, cancer in situ in 17 and skin cancer in 19); cumulative incidence 1.0% at 10 years, 2.2% at 15 years and 3.3% at 20 years, respectively. This rate was 2.1 higher than expected in a matched general population. The majority of patients in this analysis were given total body irradiation (TBI) during conditioning. In a follow-up report, Majhail et al. 9 studied 4318 patients with acute myeloid leukemia (AML) in first complete remission and chronic myeloid leukemia (CML) in chronic phase given allogeneic SCT with myeloablative chemotherapy-based conditioning consisting of busulfan and cyclophosphamide. Sixtysix patients had a secondary malignancy. The 10-year cumulative incidence was 1.2% in AML and 2.4% in CML, 1.4 times higher than expected in a general population.
Reduced-intensity conditioning (RIC) has been widely introduced over the past decade to allow SCT in older or medically infirm patients who are not eligible for standard myeloablative SCT. 10 RIC has been able to markedly expand the eligible population and the indications for SCT by reducing the incidence of early transplant-related complications. However, due to the relative limited long-term follow-up, so far, of RIC recipients, the incidence and risk-factors for secondary malignancies following RIC have not been defined. In this analysis, we show that, to the contrary of what was intuitively expected, 2 the incidence of secondary malignancies has not decreased in the era of RIC and may have even increased.
PATIENTS AND METHODS

Patient eligibility
This is a retrospective analysis of all patients given a first allogeneic SCT in a single institution between January 1999 and May 2011. This time frame was selected based on the start of implication of RIC in our institution and to allow surviving patients at least 12-month follow-up. Patients with various hematological malignancies and non-malignant disorders were treated according to the standard indications. As a general role, patients with acute leukemia who met standard eligibility criteria were given myeloablative conditioning (MAC). Patients 455 years with a sibling donor or 450 years with an unrelated donor, patients with extensive previous therapy (including a previous autologous SCT) and patients with organ dysfunction, poor performance status or significant comorbidities were preferentially given RIC or fludarabine-based reduced-toxicity MAC (RTC). Patients with lymphoproliferative disorders were also preferentially given RIC/RTC. Patients had to have an HLA (human leukocyte antigen)-compatible related or unrelated donor willing to donate G-CSF (granulocyte colony-stimulating factor)-mobilized peripheral blood stem cells (PBSC, the preferred requested option) or bone marrow (BM). Patients with no suitable donors were eligible for umbilical cord blood or haplo-identical SCT. All patients were treated on protocol approved by the institution review board and gave written informed consent. The current retrospective analysis was approved by the institution review board, as well.
Conditioning regimens
MAC included most often the combination of TBI and high-dose cyclophosphamide (Cy/TBI) or high-dose intravenous busulfan combined with high-dose cyclophosphamide (BuCy). RIC included fludarabine combined with reduced-dose of busulfan (FB2) or melphalan (FM). RTC included fludarabine and myeloablative doses of busulfan (FB4) or treosulfan (FT) as previously reported. 11 Patients with an unrelated or mismatched donor and patients with no previous chemotherapy were also given antithymocyte globulin. In vitro T-cell depletion was only used in haplo-identical transplants. Prophylaxis against graft-versus-host disease (GVHD) consisted most often of cyclosporine A and a short course of methotrexate or mycophenplate mofetil. G-CSF was administered from day þ 7 until engraftment. A standard regimen of antibiotic prophylaxis was used to prevent bacterial, viral, fungal and pneumocystis carini infections.
Follow-up and diagnosis of secondary malignancies
Patients continued life-time follow-up by their transplant physicians and complete follow-up was available for the majority. Secondary malignancies were diagnosed based on new symptoms or new laboratory and imaging findings, leading to diagnostic biopsies. Routine surveillance program for diagnosis of specific secondary malignancies was not generally used. Donor-derived MDS/AML was included with secondary malignancies and diagnosed based on diagnosis of MDS/AML but with donor chimerism. Post-transplant lymphoproliferative disorder was not considered a secondary malignancy in this analysis. Relapse of a previous malignancy that was not the indication of SCT, such as an antecedent malignancy in a patient transplanted for therapy-related AML was also not considered a secondary malignancy. Secondary malignancies were treated by oncology specialists. Standard therapy was preferentially selected when applicable depending on disease status and patient condition.
Statistical analysis
The primary end point was occurrence of a secondary malignancy. Time to diagnosis was recorded from the time of SCT to diagnosis, death or last follow-up. The incidence of secondary malignancy was estimated using cumulative incidence analysis with death due to other causes considered a competing risk. 12 Patients were not censored at the time of relapse of the original malignancy or at the administration of other therapies, including a second SCT for any reason.
The incidence of chronic GVHD and mortality due to secondary malignancies were also estimated using cumulative incidence analysis. Overall survival was calculated from the day of SCT until death or last follow-up. The probability of overall survival was estimated using the Kaplan-Meier method. 13 Cox proportional hazard model was used to determine the significance of multiple patient and disease categorical variables in determining the incidence of secondary malignancies. Factors with at least borderline statistical significance (Po0.2) were included in the final model. The conditioning regimen was always entered into the Cox model as outcomes associated with the conditioning regimen were the major purpose of analysis.
Standardized incidence ratios (SIR) were computed as ratios of observed to expected cancers, with 95% confidence intervals (CIs). Person years at risk were calculated from the date of SCT until the date of diagnosis of secondary malignancy, death or last follow-up. The observed incidence rates of secondary malignancies were compared with the incidence rates of all invasive cancers in the general population, obtained from the Israeli ministry of health database. Expected rates were based on age-, sex-, continent of birth-and calendar year-specific national cancer incidence rates for all invasive cancers combined and for cancers of specific anatomical sites. The analysis was limited to Israeli patients as the database does not include non-Israelis. The SIR analysis also did not include skin cancers that are not represented in the database.
All rates are presented with 95% CIs. All P-values are two-sided and values o0.05 were considered statistically significant.
RESULTS
Patient characteristics
The analysis included 931 adult patients given allogeneic SCT over a 13 year period in a single institution. Patient characteristics are outlined in Table 1 . The median age at SCT was 50 years (range 17-76). The conditioning regimen given before SCT was MAC (n ¼ 257), RIC (n ¼ 449) or RTC (n ¼ 225). The median follow-up of surviving patients was 55 months (12 months-13 years). The total follow-up time was 2260 patient-years. Follow-up data were available for all but 4 patients (99.5%). At the time of last followup, 328 patients were alive and the estimated 5-year survival is 34% (95% CI, 30-37). The cumulative incidence of chronic GVHD of all grades and of moderate-severe grade was 53% (95% CI, 49-57) and 37% (95% CI, 32-43), respectively.
Incidence and types of secondary malignancies Secondary malignancies occurred in 27 patients. The types and outcomes of patients with secondary malignancies are outlined in Table 2 . Nine patients had adenocarcinoma of the colon, breast, pancreas or of unknown origin; five patients had squamous cell carcinoma (SCC) of esophagus, genitalia or head and neck; eight had skin cancer (SCC or melanoma), two had sarcomas and three had donor-derived MDS/AML. In all, 10 patients had metastatic or locally advanced tumor at presentation. The median time to presentation was 43 months after SCT (7 months-11.5 years). Adenocarcinomas and non-skin SCC occurred later, median 84 months after SCT, while skin cancers, sarcomas and donor-derived MDS/AML occurred earlier after SCT, median 26 months (P ¼ 0.001). The cumulative incidence at 10 years after SCT was 5.6% (95% CI, 3.6-8.7). Three cancers were diagnosed within the first year after SCT, 13 within the first 3 years, 17 within the first 5 years, 20 within the first 7 years, 25 within the first 10 years and 2 after 10 years. The cumulative incidence at 1, 3, 5 and 7 years was 0.3% (95% CI, 0.1-1.0), 1.7% (95% CI, 1.0-2.8), 2.4% (95% CI, 1.5-3.9) and 3.3% (95% CI, 2.1-5.2), respectively ( Figure 1) .
The specific 10-year cumulative incidence of adenocarcinomas, invasive SCC, skin SCC and donor-derived MDS/AML were 2.3% (95% CI, 1.1-5.2), 1.5% (95% CI, 0.5-4.2), 1.3% (95% CI, 0.6-2.8) and 0.4% (95% CI, 0.1-1.3), respectively.
The three patients with donor-derived MDS/AML were somewhat older, age 60-70 years at SCT, two had AML and one had lymphoma. All had SCT from a matched sibling, two with RIC and one with MAC. All siblings remained healthy so far.
Most patients were given standard therapy for their secondary malignancies. Seventeen patients with operable tumor and skin tumors had surgery with additional chemotherapy and/or radiation therapy as indicated and all but one are alive. One of these patients died of complications related to chronic GVHD. Seven patients with locally advanced or metastatic malignancy were given supportive care (n ¼ 3) or chemo-radiotherapy (n ¼ 4), and six have died. Two of the three patients with donor-derived MDS/AML were given chemotherapy and second transplant from the same donor and one had supportive care alone. All the three patients died. The 10-year cumulative incidence of mortality from secondary malignancy in the entire cohort is 2.4% (95% CI, 1.0-5.4). Among patients who were alive 5 years after SCT, the estimated death rate due to secondary malignancy during the subsequent 5 years is 4.8% (95% CI, 1.6-14.6).
Three patients had post-transplant lymphoproliferative disorder, two with severe GVHD and one after a second umbilical cord blood transplantation. Post-transplant lymphoproliferative disorder was not considered with second malignancies in this analysis. Two patients who were given allogeneic SCT for AML that was related to previous chemotherapy for breast cancer had a later relapse of their original malignancy and were also not analyzed with the secondary malignancies. All five patients in these last two categories died of their malignancy.
Predicting factors for secondary malignancy Table 3 outlines the univariate and multivariate analysis of factors predicting for the occurrence of secondary malignancies. The conditioning regimen before SCT was a significant predicting factor. There were only four cases among MAC recipients (Table 2) , cumulative incidence 1.7% (95% CI, 0.5-5.1%). Three occurred in BuCy recipients, cumulative incidence 2.2% (95% CI, 0.6-8.8) for this regimen, while none of 111 TBI recipients had a secondary malignancy. The cumulative incidence was 7.4% (95% CI, 4.4-12.2) and 5.7% (95% CI, 1.8-18.3) after RIC and RTC, respectively (P ¼ 0.02 for RIC/RTC vs MAC, Figure 2 ). More specifically the cumulative incidence was 10.3, 4.7, 4.9 and 4.7% after FB2, FM, FB4 and FT, respectively. There was a lower incidence of secondary malignancies among patients with CML in chronic phase and other chronic myeloproliferative disorders (MPD), as well as in patients with non-malignant disorders, compared with other hematological malignancies.
Patients with chronic GVHD of moderate-severe grade had higher risk for secondary malignancies. Twenty-one of the 27 patients with secondary malignancy had a history of chronic GVHD that was graded moderate-severe in 14. Fifteen patients were still on immune-suppressive therapy at the time of diagnosis of secondary malignancy.
Multivariate analysis supported the independent risk associated with RIC/RTC (hazard ratio (HR) 3.5, P ¼ 0.05), moderate-severe chronic GVHD (HR 2.8, P ¼ 0.01) and a diagnosis of chronic MPD or non-malignant disease (HR 0.2, P ¼ 0.04). Advanced age and male gender were associated with higher risk in the univariate but not in the multivariate analysis. The same factors were identified when the analysis was limited to RIC/RTC recipients alone. The HR for moderate-severe chronic GVHD and MPD/non-malignant disease were 2.8 (P ¼ 0.03) and 0.2 (P ¼ 0.05), respectively.
Secondary malignancy risk compared with the general population The observed rate of secondary malignancies among transplant recipients (excluding SCC of the skin and non-Israeli patients) was 2.00 higher than expected in their age, gender, continent of birth and year of diagnosis rates (95% CI, 1.18-3.16). Calculated SIR remained higher than the general population in the RIC/RTC group, 2.05 (95% CI, 1.17-3.34). The statistical significance in the MAC group was limited due to sample size (Table 4) . Specifically, elevated risks were found in this analysis for cancers of the esophagus, pancreas and colon. Further SIR analysis of patient subsets was not possible in this sample size.
DISCUSSION
This study defines the incidence and risk factors for secondary malignancies after allogeneic SCT in the era of fludarabine-based RIC and RTC regimens. The 10-year cumulative incidence among all patients was 5.6% or twice the expected in a matched normal population (SIR 2.0). These rates seem higher than the previously reported rates in two large CIBMTR registry studies by Rizzo et al. 8 and Majhail et al., 9 showing a 10-year incidence of 1.0-2.4%. There are several possible explanations for these differences. The SCT field has markedly changed over the past decade. RIC/RTC regimens allowed expansion of SCT to older and more heavily pretreated patients. The stem-cell source has largely switched to PBSC rather than BM, and alternative sources such as umbilical cord blood and haplo-identical stem cells are increasingly been used. These changes may have modified the incidence and risk factors for late effects.
The median age at SCT in the CIBMTR studies was 27 and 34 years, respectively, and they also included pediatric patients, whereas in the current study it was 50 years, significantly higher. Older age has been recognized as an important risk factor for secondary malignancies. [4] [5] [6] 8, 9 However, reflecting the c Among patients alive at least 6 months after transplant. Statistical comparison of predicting factors is given in Table 3 .
Secondary malignancies and RIC A Shimoni et al increased background rates of malignancies in the general population with increasing age, SIR is generally not higher with age. 8, 9 Similarly, SIR 2.0 in the current study was similar to that reported in the previous studies, 2.1 and 1.4, respectively. Advanced age was identified as significant risk factor in the univariate analysis but was not significant after adjusting for other risk factors.
The conditioning regimen used is of major importance. All previous studies included only patients given MAC. TBI is a major risk factor, mostly for non-SCC tumors and when given at younger age (o30 years). 8 We have not seen a single secondary malignancy among 111 TBI recipients; however, their median age was 35 years, an age with much lower risk. We have seen three cases among 128 BuCy recipients, 10-year cumulative incidence 2.2%, similar to the CIBMTR study. 9 The major difference in incidence between the studies was related to the relatively high rates of secondary malignancies among patients given fludarabine-based RIC and RTC regimens, 7.4 and 5.7%, respectively. The multivariate analysis identified fludarabine-based RIC/RTC as an independent factor, even after adjusting for other risk factors. In accordance with recent SCT practice, RIC/RTC recipients consisted of 73% of all patients in this cohort.
The pathogenesis of secondary malignancies after allogeneic SCT is multi-factorial. Radiation and chemotherapy exposure can induce breaks in DNA double strand, resulting in gene mutations, deletions and translocations and genomic instability conferred by loss of DNA repair.
14 Genomic alterations in mucosal epithelium as evidenced by microsatellite instability are common, including in tissues affected by GVHD and may contribute to secondary malignancies. 15 Oncogenic viruses in the context of prolonged immune suppression may also take part in pathogenesis. 16 Fludarabine-based conditioning may modify these processes. Fludarabine is a purine analog that affects DNA synthesis and can also inhibit DNA repair following DNA damage. 17 Fludarabine chemotherapy has been associated with an increased rate of secondary MDS/AML and solid tumors in patients with chronic lymphocytic leukemia and indolent lymphoma. 18 The incidence increases when it is combined with cyclophosphamide or other DNAdamaging agents. 19, 20 This has been postulated to result from the synergistic effects of DNA damage and fludarabinerelated inhibition of DNA repair. It can be speculated that the combination of fludarabine with intermediated or high-dose Figure 1 . Cumulative incidence of secondary malignancies after allogeneic stem-cell transplantation. The 10-year rate is 5.6% (95% CI 3.6-8.7). Three cancers were diagnosed within the first year after SCT, 13 within the first 3 years, 17 within the first 5 years, 20 within the first 7 years, 25 within the first 10 years and 2 after 10 years.
alkylating agents as given in RIC/RTC may have a similar effect in the transplant setting and that these effects may be even more carcinogenic than that of TBI or high-dose alkylating agent alone as given in MAC.
Chronic GVHD is another strong risk factor for secondary malignancies, in particular SCC of the skin and mucusa. [7] [8] [9] It may damage target tissues and is associated with prolonged immune suppression, and both the severity and the duration of immunosuppressive therapy were implicated in the increased risk. 7 The current study also determined chronic GVHD as a major risk factor. Chronic GVHD may be more frequent among recipients of PBSC than BM. 21 Most patients in previous studies were given BM; however, SCT practice has almost completely switched to PBSC as in the current analysis.
We have observed low incidence of secondary malignancies among patients with chronic MPD and non-malignant disorders. Previous studies have also reported low incidence in CML and aplastic anemia. 3, 8 These patients are typically not exposed to chemotherapy before SCT. The relative role of pre-transplant therapies and the SCT conditioning regimen is not established as most studies compared SCT recipients with the general population and not with non-transplanted patients with chemotherapy-treated malignancies. In the current era, more heavily treated patients, such as patients with a previous autologous SCT, may become eligible for Previous studies defined the typical secondary malignancies. TBI exposure was associated with non-SCC tumors and, in particular, breast, thyroid, bone/connective tissue, brain and melanoma. 8 BuCy was associated with lung cancer as well as oral cavity, esophagus, soft tissue and brain. 9 The present study is not powered to detect the incidence and risk factors for specific anatomical sites. However, we identified high SIR for esophagus, colon and pancreatic cancers. We also observed seven patients with skin SCC; six were RIC/RTC recipients. Skin SCC has been previously associated with allogeneic as well as solid organ transplantation and appears relatively early after transplant. 22 One additional report suggested a high incidence of skin malignancies in RIC recipients. 23 Donor-derived MDS/AML is a rare and intriguing entity. A survey of the European Group for Blood and Marrow Transplantation (EBMT) estimated the incidence to be 1.2 of 1000 transplants and most occurred, as in the current study, within 4 years of SCT. 24 Most cases have historically been reported following MAC but also more recently after RIC as well. 25 The pathogenesis is not well established. According to the multiple hit theory of leukemogenesis, it can be speculated that donor stem cells already acquired a first hit (genetic or acquired) in the donor and additional hits are acquired in the host-supportive marrow microenvironment. Persistence of host oncogenic factors (such as viruses), altered immune surveillance and accelerated telomere shortening following replicative stress may also contribute. 25 Transfer of occult leukemia from the donor is extremely rare, as most donors, as in the current report, remained healthy. The type of conditioning is probably less important, as donor cells are not exposed to chemotherapy.
Secondary malignancies represent an important cause of late non-relapse mortality among long-term survivors and accounts for 5-10% of late deaths. 2 In the current study, it is estimated that 4.8% of patients surviving 5 years after SCT will succumb to secondary malignancy. Most patients can be treated according to standard therapy for their second malignancy and patients with operable or non-metastatic tumors can be cured.
The major limitation of this study is the relatively limited cohort, as can be expected from a single-center analysis. This number precludes subset analysis of specific types of secondary malignancies and determination of specific risk factors. The follow-up duration of this cohort is also limited, as RIC/RTC started to be increasingly used only a decade ago. Longer follow-up will be required to define the patterns of late malignancies 10-20 years after SCT, as already reported for myeloablative SCT.
In conclusion, secondary malignancies remain a significant risk for long-term survivors in the era of fludarabine-based RIC/RTC. The risk is not reduced and is even possibly increased. The benefit of RIC/RTC outweighs this possibly increased risk for patients who are not eligible for MAC. However, patients and physicians should be aware of this association and life-long cancer screening is required for all transplant survivors, according to established guidelines. 26 Abbreviations: CI, confidence interval; MAC, myeloablative conditioning; Pyr, patient years; RIC, reduced intensity conditioning; RTC, reduced toxicity conditioning.
a Squamous cell carcinoma of the skin and secondary malignancies in non-Israeli patients were not analyzed as they were not represented in the population database.
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